• Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD

  • Aug 26 2024
  • Length: 15 mins
  • Podcast

Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD

Listen for free

View show details

  • Summary

  • In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

     Episode outline:  

    • Colchicine: inhibition of NLRP3 inflammasome assembly/activation
    • Canakinumab (anti–IL-1β monoclonal antibody)
    • Ziltivekimab (anti–IL-6 monoclonal antibody)
    • Other emerging targets/therapies

    To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

    • CME-certified text module with animated pathophysiology video and faculty voice audio clips
    • ClinicalThought commentaries
    • Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
    • Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
    Show more Show less
Show more Show less

What listeners say about Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available